TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

NOXAFIL

POSACONAZOLE
Approved 2006-09-15
7
Indications
--
Phase 3 Trials
2
Priority Reviews
19
Years on Market

Details

Status
Discontinued
First Approved
2006-09-15
Routes
INTRAVENOUS, ORAL
Dosage Forms
SOLUTION, TABLET, DELAYED RELEASE, SUSPENSION

Companies

Active Ingredient: POSACONAZOLE

NOXAFIL Approval History

Loading approval history...

What NOXAFIL Treats

7 FDA approvals

Originally approved for its first indication in 2006 . Covers 7 distinct patient populations.

  • Other (7)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

NOXAFIL FDA Label Details

Pro

NOXAFIL Patents & Exclusivity

Latest Patent: Feb 2033
Exclusivity: Jun 2028

Patents (9 active)

US9493582 Expires Feb 27, 2033
US9023790 Expires Jul 4, 2031
US9358297 Expires Jun 24, 2031
US9750822 Expires Mar 13, 2029
US10117951 Expires Mar 13, 2029
US8410077 Expires Mar 13, 2029

Exclusivity

ODE-355 Until Jun 2028
ODE-355 Until Jun 2028
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.